title: Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
abstract: Two series of nociceptin (NC)-related peptides with or without replacement of the N-terminal Phe by Tyr have been investigated in an attempt to obtain compounds that interact with the NC receptor (ORL1) and classic opioid receptors. When tested for their ability to displace [3H]NCNH2 ([3H]nociceptin amide; ORL1 sites) or the selective opioid receptor ligands [3H]DAMGO (mu), [3H]deltorphin II (delta) and [3H]U69593 (kappa) from their respective binding sites in guinea-pig brain membranes, [Tyr1]NCNH2 and [Tyr1]NC(1-13)NH2 showed high affinities (Ki 2nM and 5 nM, respectively) for ORL1 and approximately tenfold lower potency for mu (32nM and 44nM) and kappa sites (42 nM and 48 nM). They also interacted, but with low potency (Ki 410 nM and 310 nM) with delta sites. Shorter fragments as [Tyr1]NC(1-9)NH2 and [Tyr1]NC(1-5)NH2 were found to be inactive on ORL1, delta and kappa sites, and extremely weak (Ki 2224 nM and 4228 nM, respectively) on mu. Results of bioassays performed on the guinea-pig ileum (ORL1 and mu receptors), mouse vas deferens (ORL1 and delta receptors), and rabbit vas deferens (kappa receptor) confirmed (at least partially) the data of the binding by showing that [Tyr1]NC analogs interact with functional ORL1 as well as with classic opioid receptors. [Tyr1]NCNH2 and [Tyr1]NC(1-13)NH2 behaved as mixed ORL1/opioid receptor agonists showing similar affinities as the control NC sequence while [Tyr1]NC(1-9)NH2 and [Tyr1]NC(1-5)NH2 were inactive on ORL1 receptors but maintained some activities on opioid receptors: their effects were prevented by naloxone. The results of this study indicate that the replacement of Phe1 by Tyr in NC leads to compounds which bind both the ORL1 and mu/kappa receptors and may represent new promising agents for use in peripheral organs.
authors.affiliation: Department of Experimental and Clinical Medicine, University of Ferrara, Italy.
authors.forename: K
authors.initials: K
authors.lastname: Varani
authors.forename: A
authors.initials: A
authors.lastname: Rizzi
authors.forename: G
authors.initials: G
authors.lastname: Calo
authors.forename: R
authors.initials: R
authors.lastname: Bigoni
authors.forename: G
authors.initials: G
authors.lastname: Toth
authors.forename: R
authors.initials: R
authors.lastname: Guerrini
authors.forename: S
authors.initials: S
authors.lastname: Gessi
authors.forename: S
authors.initials: S
authors.lastname: Salvadori
authors.forename: P A
authors.initials: PA
authors.lastname: Borea
authors.forename: D
authors.initials: D
authors.lastname: Regoli
mesh_terms: D019943:Amino Acid Substitution; D000818:Animals; D044482:Benzeneacetamides; D001665:Binding Sites; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000378:metabolism; D006168:Guinea Pigs; D007082:Ileum / Q000378:metabolism; D008297:Male; D008566:Membranes / Q000378:metabolism; D051379:Mice; D009842:Oligopeptides / Q000378:metabolism; D018847:Opioid Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011759:Pyrrolidines / Q000378:metabolism; D011817:Rabbits; D011869:Radioligand Assay; D011957:Receptors, Opioid / Q000378:metabolism; D017465:Receptors, Opioid, delta / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000378:metabolism; D014316:Tritium; D014443:Tyrosine; D014649:Vas Deferens / Q000378:metabolism; D000094942:Nociceptin Receptor; D000097629:Nociceptin
chemical_list: D044482:Benzeneacetamides; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009842:Oligopeptides; D018847:Opioid Peptides; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D014316:Tritium; D014443:Tyrosine; D000094942:Nociceptin Receptor; D000097629:Nociceptin; C060209:deltorphin II, Ala(2)-; C045444:U 69593